Skip to main content

Codexis, Inc. (CDXS)

Stock NASDAQ

$1.01

-0.04 (-3.81%)

Delayed quote.

Price history

Daily close
CDXS daily closing price, Nov 24, 2025 to Nov 20, 2026 Closed at $1.59 on Nov 24, 2025 and $1.01 on Nov 20, 2026, a change of -36.48%. Range $0.96 to $2.85.
Daily closes, Nov 24, 2025 to Nov 20, 2026 (250 trading days).
Start
$1.59
Latest close
$1.01
Period change
-36.48%
Period low
$0.96
Period high
$2.85

Key metrics

Market cap
$110.69M
Volume
2.07M
Average volume
1.11M
52-week range
$0.90 – $2.98
Beta
2.39
Last dividend
—
EPS (TTM)
-$0.20
P/E ratio
-3.26
Revenue (TTM)
$88.34M
Net income (TTM)
-$19.24M
Total assets
$144.22M
Total debt
$72.27M
Cash and equivalents
$29.21M

Key financials (trailing twelve months).

Company profile

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
CEO
Alison Moore
Employees
146
Headquarters
Redwood City, CA, US
IPO date
2010-04-22

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$70.39M$59.34M$70.14M
Gross profit$61.05M$43.06M$57.33M
Operating income-$38.33M-$58.52M-$68.07M
EBITDA-$33.87M-$53.41M-$44.88M
Net income-$43.97M-$65.28M-$76.24M
Diluted EPS-$0.50-$0.89-$1.12
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$50.79M$19.26M$65.12M
Total assets$147.80M$149.01M$136.56M
Total liabilities$97.27M$82.08M$49.95M
Total debt$73.21M$59.90M$16.02M
Shareholders’ equity$50.53M$66.93M$86.61M
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow-$19.38M-$49.41M-$52.64M
Capital expenditure-$4.47M-$4.30M-$4.42M
Free cash flow-$23.85M-$53.72M-$57.06M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$19.26M$14.91M$15.25M$38.91M$8.60M$15.33M
Gross profit$15.25M$11.40M$11.94M$35.55M$6.14M$11.93M
Operating income-$7.44M-$11.23M-$8.04M$13.96M-$18.95M-$12.86M
EBITDA-$5.64M-$9.84M-$6.45M$11.84M-$16.22M-$11.26M
Net income-$8.13M-$12.01M-$8.70M$9.60M-$19.61M-$13.27M
Diluted EPS-$0.08-$0.13-$0.10$0.11-$0.22-$0.16
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$29.21M$27.17M$37.00M$50.79M$25.84M$26.76M
Total assets$144.22M$120.06M$129.37M$147.80M$123.96M$138.25M
Total liabilities$92.98M$87.10M$86.14M$97.27M$85.42M$82.61M
Total debt$72.27M$72.59M$72.90M$73.21M$68.62M$68.98M
Shareholders’ equity$51.24M$32.96M$43.23M$50.53M$38.54M$55.63M
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow-$7.77M-$9.64M-$13.15M$20.09M-$7.70M-$17.97M
Capital expenditure-$74.0K-$898.0K-$176.0K-$520.0K-$182.0K-$2.51M
Free cash flow-$7.84M-$10.54M-$13.33M$19.57M-$7.88M-$20.48M